Does the media prefer ALVO or ORKA?

In the previous week, Oruka Therapeutics had 5 more articles in the media than Alvotech. MarketBeat recorded 7 mentions for Oruka Therapeutics and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.84 beat Oruka Therapeutics' score of -0.07 indicating that Alvotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Oruka Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TVTX or ALVO?

In the previous week, Travere Therapeutics had 7 more articles in the media than Alvotech. MarketBeat recorded 9 mentions for Travere Therapeutics and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.84 beat Travere Therapeutics' score of 1.02 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alvotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor COGT or ALVO?

In the previous week, Cogent Biosciences had 2 more articles in the media than Alvotech. MarketBeat recorded 4 mentions for Cogent Biosciences and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.84 beat Cogent Biosciences' score of 0.81 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alvotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to KNSA or ALVO?

In the previous week, Kiniksa Pharmaceuticals International had 1 more articles in the media than Alvotech. MarketBeat recorded 3 mentions for Kiniksa Pharmaceuticals International and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.84 beat Kiniksa Pharmaceuticals International's score of 1.01 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alvotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer DNTH or ALVO?

In the previous week, Dianthus Therapeutics had 4 more articles in the media than Alvotech. MarketBeat recorded 6 mentions for Dianthus Therapeutics and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.84 beat Dianthus Therapeutics' score of 0.93 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alvotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Alvotech (ALVO) Competitors

$5.29 +0.05 (+0.95%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$5.30 +0.01 (+0.28%)

As of 09/11/2026 07:30 PM Eastern

Compare

ALVO vs. ORKA, TVTX, COGT, KNSA, and DNTH

Should you buy Alvotech stock or one of its competitors? Alvotech's main competitors and comparable companies include Oruka Therapeutics (ORKA), Travere Therapeutics (TVTX), Cogent Biosciences (COGT), Kiniksa Pharmaceuticals International (KNSA), and Dianthus Therapeutics (DNTH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alvotech compare to Oruka Therapeutics?

Alvotech (NASDAQ:ALVO) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Oruka Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -36.31%. Alvotech's return on equity of -11.92% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-36.31%	-11.92%	-11.73%
Oruka Therapeutics	N/A	-21.65%	-20.88%

Alvotech has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$491.95M	3.25	$27.92M	-$0.61	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

Alvotech has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, meaning that its share price is 134% less volatile than the broader market.

In the previous week, Oruka Therapeutics had 5 more articles in the media than Alvotech. MarketBeat recorded 7 mentions for Oruka Therapeutics and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.84 beat Oruka Therapeutics' score of -0.07 indicating that Alvotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Oruka Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

56.4% of Oruka Therapeutics shares are owned by institutional investors. 0.5% of Alvotech shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Alvotech presently has a consensus target price of $7.50, suggesting a potential upside of 41.78%. Oruka Therapeutics has a consensus target price of $133.00, suggesting a potential upside of 43.97%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Oruka Therapeutics is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.25
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

Alvotech beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Alvotech compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Alvotech (NASDAQ:ALVO) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Travere Therapeutics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market.

Travere Therapeutics has a net margin of -7.35% compared to Alvotech's net margin of -36.31%. Alvotech's return on equity of -11.92% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-7.35%	-55.15%	-6.88%
Alvotech	-36.31%	-11.92%	-11.73%

In the previous week, Travere Therapeutics had 7 more articles in the media than Alvotech. MarketBeat recorded 9 mentions for Travere Therapeutics and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.84 beat Travere Therapeutics' score of 1.02 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alvotech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Alvotech has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$591.33M	10.55	-$25.55M	-$0.46	N/A
Alvotech	$491.95M	3.25	$27.92M	-$0.61	N/A

Travere Therapeutics currently has a consensus price target of $68.00, indicating a potential upside of 2.77%. Alvotech has a consensus price target of $7.50, indicating a potential upside of 41.78%. Given Alvotech's higher possible upside, analysts plainly believe Alvotech is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Alvotech	2 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Travere Therapeutics beats Alvotech on 9 of the 14 factors compared between the two stocks.

How does Alvotech compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Alvotech (NASDAQ:ALVO) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Alvotech has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
Alvotech	$491.95M	3.25	$27.92M	-$0.61	N/A

Cogent Biosciences has a net margin of 0.00% compared to Alvotech's net margin of -36.31%. Alvotech's return on equity of -11.92% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
Alvotech	-36.31%	-11.92%	-11.73%

In the previous week, Cogent Biosciences had 2 more articles in the media than Alvotech. MarketBeat recorded 4 mentions for Cogent Biosciences and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.84 beat Cogent Biosciences' score of 0.81 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alvotech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cogent Biosciences has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

Cogent Biosciences currently has a consensus target price of $51.56, suggesting a potential upside of 54.31%. Alvotech has a consensus target price of $7.50, suggesting a potential upside of 41.78%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Cogent Biosciences is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Alvotech	2 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Cogent Biosciences and Alvotech tied by winning 7 of the 14 factors compared between the two stocks.

How does Alvotech compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Alvotech (NASDAQ:ALVO) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$840.85M	7.08	$59.01M	$0.97	78.63
Alvotech	$491.95M	3.25	$27.92M	-$0.61	N/A

Kiniksa Pharmaceuticals International has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market.

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 0.5% of Alvotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Alvotech's net margin of -36.31%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Alvotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
Alvotech	-36.31%	-11.92%	-11.73%

In the previous week, Kiniksa Pharmaceuticals International had 1 more articles in the media than Alvotech. MarketBeat recorded 3 mentions for Kiniksa Pharmaceuticals International and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.84 beat Kiniksa Pharmaceuticals International's score of 1.01 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alvotech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Kiniksa Pharmaceuticals International currently has a consensus target price of $87.38, suggesting a potential upside of 14.56%. Alvotech has a consensus target price of $7.50, suggesting a potential upside of 41.78%. Given Alvotech's higher possible upside, analysts clearly believe Alvotech is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Alvotech	2 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Kiniksa Pharmaceuticals International beats Alvotech on 13 of the 16 factors compared between the two stocks.

How does Alvotech compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Alvotech (NASDAQ:ALVO) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Dianthus Therapeutics has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market.

In the previous week, Dianthus Therapeutics had 4 more articles in the media than Alvotech. MarketBeat recorded 6 mentions for Dianthus Therapeutics and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.84 beat Dianthus Therapeutics' score of 0.93 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alvotech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Dianthus Therapeutics presently has a consensus target price of $129.83, indicating a potential upside of 22.25%. Alvotech has a consensus target price of $7.50, indicating a potential upside of 41.78%. Given Alvotech's higher probable upside, analysts plainly believe Alvotech is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Alvotech	2 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.25

47.5% of Dianthus Therapeutics shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 0.5% of Alvotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Alvotech has a net margin of -36.31% compared to Dianthus Therapeutics' net margin of -10,096.95%. Alvotech's return on equity of -11.92% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
Alvotech	-36.31%	-11.92%	-11.73%

Alvotech has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,846.06	-$162.34M	-$4.15	N/A
Alvotech	$491.95M	3.25	$27.92M	-$0.61	N/A

Summary

Alvotech beats Dianthus Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Alvotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALVO vs. The Competition

Export

Metric	Alvotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.60B	$3.84B	$7.14B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-8.67	14.25	275.24	25.29
Price / Sales	3.25	1,473.16	656.02	98.94
Price / Cash	24.05	106.68	77.04	51.44
Price / Book	-5.63	15.12	10.33	6.20
Net Income	$27.92M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-0.56%	-4.34%	-3.32%	-2.35%
1 Month Performance	31.92%	-0.02%	-0.41%	-2.77%
1 Year Performance	-34.12%	40.64%	19.21%	7.63%

Alvotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALVO Alvotech	3.1137 of 5 stars	$5.29 +1.0%	$7.50 +41.8%	-34.3%	$1.60B	$491.95M	N/A	1,279	Positive News
ORKA Oruka Therapeutics	3.3544 of 5 stars	$94.42 +2.1%	$133.00 +40.9%	+472.0%	$6.25B	N/A	N/A	N/A
TVTX Travere Therapeutics	1.6601 of 5 stars	$66.01 +1.1%	$61.67 -6.6%	+164.7%	$6.22B	$490.73M	N/A	460	Positive News Insider Trade
COGT Cogent Biosciences	1.8998 of 5 stars	$35.26 +1.4%	$51.56 +46.2%	+160.8%	$6.12B	N/A	N/A	80
KNSA Kiniksa Pharmaceuticals International	4.0276 of 5 stars	$76.96 -1.2%	$87.38 +13.5%	+106.1%	$6.00B	$677.56M	79.34	220	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALVO) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alvotech (ALVO) Competitors

ALVO vs. ORKA, TVTX, COGT, KNSA, and DNTH

How does Alvotech compare to Oruka Therapeutics?

Summary

How does Alvotech compare to Travere Therapeutics?

Summary

How does Alvotech compare to Cogent Biosciences?

Summary

How does Alvotech compare to Kiniksa Pharmaceuticals International?

Summary

How does Alvotech compare to Dianthus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO vs. The Competition

Alvotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alvotech (ALVO) Competitors

ALVO vs. ORKA, TVTX, COGT, KNSA, and DNTH

How does Alvotech compare to Oruka Therapeutics?

Is ALVO or ORKA more profitable?

Which has better earnings & valuation, ALVO or ORKA?

Which has more risk and volatility, ALVO or ORKA?

Does the media prefer ALVO or ORKA?

Do insiders and institutionals have more ownership in ALVO or ORKA?

Do analysts rate ALVO or ORKA?

Summary

How does Alvotech compare to Travere Therapeutics?

Which has more volatility & risk, TVTX or ALVO?

Is TVTX or ALVO more profitable?

Does the media favor TVTX or ALVO?

Which has better valuation & earnings, TVTX or ALVO?

Do analysts recommend TVTX or ALVO?

Summary

How does Alvotech compare to Cogent Biosciences?

Which has better valuation and earnings, COGT or ALVO?

Is COGT or ALVO more profitable?

Does the media favor COGT or ALVO?

Which has more risk & volatility, COGT or ALVO?

Do analysts recommend COGT or ALVO?

Summary

How does Alvotech compare to Kiniksa Pharmaceuticals International?

Which has better valuation and earnings, KNSA or ALVO?

Which has more risk & volatility, KNSA or ALVO?

Do insiders & institutionals hold more shares of KNSA or ALVO?

Is KNSA or ALVO more profitable?

Does the media refer more to KNSA or ALVO?

Do analysts recommend KNSA or ALVO?

Summary

How does Alvotech compare to Dianthus Therapeutics?

Which has more volatility and risk, DNTH or ALVO?

Does the media prefer DNTH or ALVO?

Do analysts recommend DNTH or ALVO?

Do institutionals & insiders believe in DNTH or ALVO?

Is DNTH or ALVO more profitable?

Which has better earnings and valuation, DNTH or ALVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO vs. The Competition

Alvotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools